Accord logo
A new online gateway to match your expertise
info icon

This promotional site is intended for United Kingdom (UK) healthcare professionals and other relevant decision makers only. If you are a member of the public, please click here.

info

Adverse events reporting statement can be found at the bottom of this webpage. Click here to access Prescribing Information.

One & Only: Oral ADT for your prostate cancer patients

Relugolix▼ (ORGOVYX®) can be prescribed to a range of men with prostate cancer, as recommended by NICE and accepted by SMC:1-3

  • Adult patients with advanced hormone-sensitive prostate cancer1
  • High-risk localised and locally advanced hormone dependent prostate
cancer in combination with radiotherapy1
  • High-risk localised and locally advanced hormone dependent prostate
cancer as a neo-adjuvant treatment prior to radiotherapy1

On Accord Engage, you can find a wealth of information and resources on relugolix oral ADT. You can learn important differences between GnRH agonists and antagonists – and their associated outcomes. There are also resources available to support patient discussions where appropriate.

Please refer to the SmPC for a full list of adverse events associated with ORGOVYX®▼ (relugolix) therapy.
REGISTER NOWto access the latest relugolix information

img
Healthcare Professional Information & Resources
call to action banner

ARRANGE A MEETING

Arrange a meeting with an Accord Key Account Manager today

Schedule here

More articles and presentations

prostate-cancer-treatment

The Unmentionables: Podcast

Podcast series hosted by Jeff Stelling helping people to talk openly about what matters most in prostate cancer. This podcast is for people diagnosed with prostate cancer and their families.

Listen Here
prostate-cancer-treatmentvideo play icon

PROSCA 2024 Satellite Symposium: Professor Athanasios Papatsoris

At PROSCA 2024, Prof Athanasios Papatsoris shares insights on the role and impact of oral ADT in clinical practice, drawing from his first-hand experience and clinical expertise.

Duration : 02:35 min
Watch Video
prostate-cancer-treatment

Medical Education

Read more
References:
  1. ORGOVYX® Summary of Product Characteristics.
  2. National Institute for Health and Care Excellence. Relugolix for treating hormone-sensitive prostate cancer. 2024. Available at: https://www.nice.org.uk/guidance/ta995/ (accessed October 2025).
  3. Scottish Medicines Consortium: SMC. Relugolix film-coated tablets (Orgovyx®). Available at:  https://scottishmedicines.org.uk/medicines-advice/relugolix-orgovyx-full-smc2678/ (Accessed October 2025).

 

Abbreviations:
ADT, androgen deprivation therapy
CV, cardiovascular
CVD, cardiovascular disease
GnRH, gonadotropin-releasing hormone
IPSS, international prostate symptom score
LHRH, luteinizing-hormone releasing hormone
LUTS, lower urinary tract symptoms
MDT, multidisciplinary team
PSA, prostate specific antigen
SHBG, sex hormone binding globulin

Job Code: UK-Onc-Org-02191 | Date of Preparation: December 2025